Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Dwain Tolbert"'
Autor:
Frank Larsen, Dwain Tolbert
Publikováno v:
Journal of Clinical Pharmacology
Clobazam (CLB) is a 1,5‐benzodiazepine that has been widely used as an anxiolytic and antiseizure drug (ASD) since it was first synthesized over 50 years ago. CLB was approved in the United States in 2011 as adjunctive therapy for seizures in patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fb129621048514a00ac0e65f9aed727
https://doi.org/10.1002/jcph.1313
https://doi.org/10.1002/jcph.1313
Autor:
Pavel Klein, Dwain Tolbert
Publikováno v:
Expert Review of Neurotherapeutics. 17:851-860
Oral carbamazepine (CBZ), a broad-spectrum antiseizure drug (ASD) widely used for over 50 years, remains an important treatment choice for focal (partial) epilepsy. Although CBZ is a known inducer of cytochrome P450 (CYP) isoenzymes, many prescribers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::844d2e163faca3f8884f978951b476c5
https://doi.org/10.1080/14737175.2017.1364993
https://doi.org/10.1080/14737175.2017.1364993
Publikováno v:
Epilepsybehavior : EB. 99
Objective The goal of this study was to characterize the drug–drug interactions between clobazam and 2 antiseizure drugs, cannabidiol and stiripentol, for treatment of refractory seizures through the use of pharmacokinetic modeling. Methods A popul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d79b648be8abc80bb3a2d0e38724af30
https://pubmed.ncbi.nlm.nih.gov/31519475
https://pubmed.ncbi.nlm.nih.gov/31519475
Publikováno v:
Epilepsy research. 157
To describe the use of a population pharmacokinetic (PopPK) model incorporating weight and ontogeny to identify effective clobazam (CLB) dosing for use in a clinical trial in pediatric patients with Dravet syndrome.Pharmacokinetic data were combined
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8654470ca3a765f656ec57e77ef90156
https://pubmed.ncbi.nlm.nih.gov/31563030
https://pubmed.ncbi.nlm.nih.gov/31563030
Publikováno v:
The Journal of Clinical Pharmacology. 56:365-374
A metabolic mechanism-based characterization of antiepileptic drug-drug interactions (DDIs) with clobazam in patients with Lennox-Gastaut syndrome (LGS) was performed using a population pharmacokinetic (PPK) approach. To characterize potential DDIs w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea099ce8ee9245b6f308da90ff525819
https://doi.org/10.1002/jcph.603
https://doi.org/10.1002/jcph.603
Publikováno v:
The Journal of Clinical Pharmacology. 56:213-222
An integrative population pharmacokinetics (PPK)-based approach was used to characterize the effect of hepatic impairment on clobazam PK and its major metabolite in systemic circulation, N-desmethylclobazam (N-CLB). At therapeutic clobazam dosages, N
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ab8e61b0918b0d6f25df400404446f83
https://doi.org/10.1002/jcph.586
https://doi.org/10.1002/jcph.586
Publikováno v:
Clinical therapeutics. 39(10)
Purpose A thorough QT study was conducted to assess the proarrhythmic potential of clobazam and its active metabolite, N-desmethylclobazam (N-CLB). Methods In this Phase I, single-site, randomized, double-blind, double-dummy, parallel-group study, he
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5a2c30d9b8d798e6bbf2f11890aa214
https://pubmed.ncbi.nlm.nih.gov/28958437
https://pubmed.ncbi.nlm.nih.gov/28958437
Autor:
David L. Wesche, Mahlaqa Patel, Jace Nielsen, Kenneth G. Kowalski, Matthew M. Hutmacher, Dwain Tolbert
Publikováno v:
The Journal of Clinical Pharmacology. 55:81-92
Vigabatrin is an irreversible inhibitor of γ-aminobutyric acid transaminase (GABA-T) and is used as an adjunctive therapy for adult patients with refractory complex partial seizures (rCPS). The purpose of this investigation was to describe the relat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::974cae64de79802b55a3ef893bc29643
https://doi.org/10.1002/jcph.378
https://doi.org/10.1002/jcph.378
Publikováno v:
Epilepsy & Behavior. 37:11-15
To assess withdrawal-related adverse event (AE) rates following abrupt clobazam discontinuation in Phase I trials and gradual clobazam tapering (2-3 weeks) following discontinuation from III trials met the criteria for potential/III trials, we evalua
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6072fc15c6a28b598d8195290515450
https://doi.org/10.1016/j.yebeh.2014.05.016
https://doi.org/10.1016/j.yebeh.2014.05.016
Publikováno v:
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 32:340-353
Study objective To investigate potential drug-drug interactions between clobazam and cytochrome P450 (CYP) isoenzyme substrates, inhibitors, and inducers. Design Two, prospective, open-label, single-center, drug-drug interaction (DDI) studies and a p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4d8dcb9ed181f0187fff580447117e4
https://doi.org/10.1002/j.1875-9114.2012.01028.x
https://doi.org/10.1002/j.1875-9114.2012.01028.x